Results 191 to 200 of about 2,467,830 (354)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Merging Micellar Catalysis and C-H Activation: Silver-Free Direct Arylation of Fluoroarenes in Water. [PDF]

ChemSusChem
Belnome F, Garami KN, Varga Z, Mihály J, Hauk P, Hergert T, Keserű GM, Gallou F, Wencel-Delord J, Ábrányi-Balogh P.   +9 more
europepmc   +1 more source

Template assisted para C-H activation

, 2018
Soumya Kumar Sinha, Sheuli Sasmal, Goutam Kumar Lahiri, Debabrata Maiti   +3 more
openalex   +1 more source

Pressure‐Enhanced C–H Bond Activation in Chloromethane Platinum(II) Complexes [PDF]

, 2019
Dominik Schmitz, Marcel Kalter, Andrew C. Dunbar, Marcel Vöst, Andreas Fischer, Kilian Batke, Georg Eickerling, Klaus Ruhland, J. Ebad-Allah, C. A. Kuntscher, Wolfgang Scherer   +10 more
openalex   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Half-Sandwich d⁶-Metal (Co^III, Rh^III, Ir^III, Ru^II)-Catalyzed Enantioselective C–H Activation

SynOpen, 2023
Pu-Fan Qian, Jun-Yi Li, Yi-Bo Zhou, Tao Zhou, Bing-Feng Shi   +4 more
doaj   +1 more source

Molecular Basis of α-Glycine C-H Activation by a Nonheme Fe(II)/2-Oxoglutarate Dioxygenase. [PDF]

Biochemistry
Chen M, Wanniarachchi TN, Caranto JD, Seabra G, Bruner SD, Ding Y.   +5 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Formal Diels-Alder reaction of saturated carboxylic acids via C-H activation. [PDF]

Nat Chem
He Q, Lu Y, Sheng T, Chekshin N, Yan JL, Zhang T, Yu JQ.   +6 more
europepmc   +1 more source